Skip to Main Content

Paper Details

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
Neurology
92
2019
EID, JC, JC virus, MS, Natalizumab, PML, SID, multiple sclerosis, natalizumab, patients, progressive multifocal leukoencephalopathy
Author NameAffiliation
Gary CutterNew York University, New York Rocky Mountain MS Clinic (J.F., MA University of Alabama School of Public Health (G.C.), New York University School of Medicine
Judith D GoldbergNew York University, New York Rocky Mountain MS Clinic (J.F., MA University of Alabama School of Public Health (G.C.), New York University School of Medicine
Judith D GoldbergNew York University, New York Rocky Mountain MS Clinic (J.F., MA University of Alabama School of Public Health (G.C.), New York University School of Medicine
  • 1 - 3

Datasets

Release 1.2